2008 BIO International Convention Exhibitor Profiles
June 13, 2008
The 2008 BIO International Convention takes place June 17, 2008 – June 20, 2008 in San Diego at the San Diego Convention Center. Listed below are the 2008 BIO International Convention exhibitor profiles.
For in-depth information about the 2008 BIO International Convention, visit http://www.bio2008.org/.
Business Wire is the official news wire for the 2008 BIO International Convention. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire’s trade show, conference, and event news resource.
Company: Addex Pharma Ticker Symbol & Exchange: ADXN Media Contact: Chris Maggos Phone: +41 22 884 15 11 E-mail: chris.maggos@addexpharma.com Web: www.addexpharma.com Addex Pharmaceuticals Ltd discovers and develops allosteric modulators, an emerging class of small molecule therapeutic agents. Allosteric modulation may offer more sophisticated ways to normalize biological signaling compared to classical orthosteric agonist or antagonist drugs. Lead product, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), showed clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) and migraine. The company has 12 early stage products. The Addex allosteric modulation discovery and development platform has been additionally validated through product collaborations with Merck & Co., Inc. and Johnson & Johnson. Company: Alston & Bird LLP Booth: 616 Media Contact: Glenda Darrell Phone: 919-862-2299 E-mail: glenda.darrell@alston.com Web: www.alston.com Alston & Bird LLP, an 800-attorney national law firm, provides life sciences expertise to established businesses, universities and startups. Our multi-disciplinary team includes members practicing in the areas of FDA, health policy, intellectual property, regulatory and compliance, products liability, business transactions and finance. Among our team members are former U.S. Senate majority leaders, Senator Bob Dole and Senator Tom Daschle, former CMS Administrator Tom Scully and a former Associate FDA Commissioner. Our group also includes members who collectively hold more than 30 life sciences degrees, 16 of which are doctorates. Alston & Bird’s attorneys have been recognized by BTI as 5th in the U.S. on its “Masters of the Deal” list. For the ninth consecutive year, Alston & Bird has been included on Fortune(R) magazine’s “100 Best Companies to Work for(TM)” list. Company: Aragen Bioscience Booth: 2321 Media Contact: Kenneth Meek Phone: 408-779-1700×13 E-mail: kmeek@aragenbio.com Web: http://www.aragenbio.com Aragen Bioscience offers molecular and cell biology and immunology services to the biotech industry. Our corporate offices and laboratories are located in Morgan Hill, California, at the south end of the Silicon Valley. Aragen and its predecessor, Sierra BioSource, have operated from this location for over 14 years. Below are a few of the custom services offered: –Hybridoma and recombinant cell line development –Cloning and protein expression in multiple platforms –Cell banking –Stemcell isolation –Pharmacokinetic and toxicity studies –Efficacy studies in various oncology, cardiovascular, and immunological disease models –In vivo model development –Ex vivo / in vitro functional analysis –Cell-based assay development for large and small molecules –Directed research programs –Small to intermediate scale production of antibodies and recombinant proteins Company: Axcela Consulting Booth: 5444 Media Contact: Stacey Stewart, Ph.D., President Phone: 480-993-2398 E-mail: stacey@axcelaconsulting.com Web: www.axcelaconsulting.com Axcela Consulting is your time-share with an experienced sales professional. We offer a la carte services to reach your target customers through e-mail, web, mail, phone, tradeshows, in-person visits and networking opportunities. Our approach is to modify your marketing message from technology-based to solutions-based….your business will soar when you help your customers solve their problems! For the BIO Conference, Axcela Consulting is offering a Postcard Design and Mailing Campaign to reach 3,000 customers for $2,500. Stop by and meet us at Booth #5444 for more details. We look forward to working with you to grow your revenue to new levels! Company: BioFocus DPI Booth: 416 Ticker Symbol & Exchange: Euronext: GLPG; OTC:GLPYY Media Contact: Maria Patey, De Facto Communications Phone: +44 (0) 207 861 3838 E-mail: m.patey@defacto.com Web: www.biofocusdpi.com BioFocus DPI is the drug discovery service division of Galapagos, offering a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies. The Company provides adenoviral reagents for rapid identification and validation of novel drug targets, natural and synthetic compound libraries for drug screening, chemogenomics and ADME database products to select targets and compounds, and compound management facilities for compound delivery to multiple screening centers. A leading discovery partner with the ability to execute turn-key deals, BioFocus DPI boasts a powerful top five position in drug discovery services worldwide. Company: Burrill & Company Media Contact: Burrill Media Phone: 415-591-5400 E-mail: events@b-c.com Web: www.burrillandco.com Burrill & Company is a global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. Burrill Media produces worldwide conferences, bio-intelligence reports and The Journal of Life Sciences. Burrill’s flagship publication is its “State of the Industry”- the latest edition is Biotech 2008: Life Sciences – A 20/20 Vision to 2020 providing a detailed analysis on the life sciences industry. Company: Crucell N.V. Ticker Symbol & Exchange: CRXL, NASDAQ & Euronext Media Contact: David Hager Phone: +31 71 519 324 E-mail: david.hager@crucell.com Web: www.crucell.com Crucell is a fully-integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases. We are the largest independent vaccine company in the world. Crucell has a broad development pipeline, including vaccines and proteins. Several Crucell products are based on our unique PER.C6(R) production technology. Crucell licenses this and other cutting edge technologies. Crucell has developed proprietary cutting-edge technologies to develop a range of biological products, or “biologics”. (1) PER.C6(R) technology, which uses human cell lines for the high yield production and large scale manufacturing of antibodies, recombinant proteins, vaccines and gene therapeutics (2) AdVac(R) technology, which is used with PER.C6(R) technology to develop novel recombinant vaccines (3) MAbstract(R) technology, for isolation of target-specific antibodies Company: Do-Coop Technologies Booth: 2401 Media Contact: Chen Guttman Phone: 972-54-6384133 E-mail: chen@docoop.com Web: www.docoop.com Do-Coop Technologies Ltd. has developed a patented Nanotechnology to modify the properties of water using nanoparticles that enables the first ever introduction of water-based biomaterials known as Neowater(R). Neowater(R) is a commercially available broad enabling platform upon which research, diagnostics, biotech and pharma companies can obtain better price-performance results and overcome current technology barriers. This technology has significant value-added drug delivery applications due to increased stability and bioavailability of hydrophilic and hydrophobic compounds solvated with Neowater(R) and without or with less organic solvents. Drug development can be enhanced and expedited when utilizing Neowater(R) in the process of compound solubilization. Company: Eden Biodesign Booth: 1043 Media Contact: Maria Patey, De Facto Communications Phone: +44 (0) 207 861 3838 E-mail: m.patey@defacto.com Web: www.edenbiodesign.com A world leader in biopharmaceutical development and cGMP manufacture, Eden Biodesign specialises in: clinical trial manufacturing, process and analytical development services, and strategic consultancy. Located in the UK, Eden has developed state-of-the-art facilities and has the scope and capacity to handle over 95% of the products and processes found within the biopharmaceutical pipeline. Eden Biodesign is committed to establishing a base in the US and founded its subsidiary, Eden Biodesign Inc., in November 2007. Eden Biodesign Inc. forms a major part of the company’s future growth strategy and further strengthens its Contract Biomanufacturing capabilities. Company: Evotec AG Ticker Symbol & Exchange: EVT (FSE) and EVTC (NASDAQ) Media Contact: Maria Patey, De Facto Communications Phone: +44 (0) 207 861 3838 E-mail: m.patey@defacto.com Web: www.evotec.com Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform applicable to targets across all therapeutic areas and has specific expertise in the area of CNS related diseases where it is building a pipeline of drug candidates for partnering. In addition it provides research collaborations to its partners in the pharmaceutical and biotechnology industries. In May, Evotec announced the completion of its acquisition of Renovis (traded formerly on NASDAQ: RNVS). Evotec is a high performance organization that manages for innovation and efficiency across all areas and currently has 3 clinical candidates and 4 late stage preclinical programmes. Company: Genetic Immunity Media Contact: Janine McCargo Phone: 646-536-7033 E-mail: jmccargo@theruthgroup.com Web: www.geneticimmunity.com Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company focused on the discovery, development and commercialization of topically administered Nanomedicines for targeted immune amplification. The Company’s Nanomedicine platform focuses on significant unmet medical needs such as infectious diseases, cancer and allergies. The DermaVir Patch, Genetic Immunity’s lead Nanomedicine candidate, is in Phase II clinical development and could be the first Nanomedicine approved for HIV/AIDS. Phase I/II trials to date of the DermaVir Patch have confirmed safety and tolerability and the amplification of HIV-specific T cell precursors (PHPC), which correlate with decreased viral load (Caralota et al, J Immunol 2008). Company: Genzyme Corporation Booth: 3727 Ticker Symbol & Exchange: Nasdaq GENZ Media Contact: Erin Emlock Phone: 617-768-6923 Web: www.genzyme.com One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees worldwide and 2007 revenues of $3.8 billion. The company’s products and services are focused on genetic diseases, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. Company: Global IP Net Booth: EC52 Media Contact: Charlene Wilson Phone: 808-891-0099 E-mail: cwilson@globalip.com Web: www.portfoliocosts.com Predict and Analyze costs for your Portfolio of patents! The Portfolio Cost Analyzer is a unique computer program which calculates current and future costs for prosecuting and maintaining your patent portfolio. The portfolio may be analyzed by any number of groups, and any combination of groups. Examples of groups are Company Divisions, Technology Types, Managers. The Analysis provides costs totaled by year, by quarter or by month, for any given range of dates. Visit http://www.portfoliocosts.com. or http://www.globalip.com Company: invivosciences LLC Booth: 1401 Media Contact: Ayla Annac Phone: 608-628-8035 E-mail: aannac@invivosciences.com Web: www.invivosciences.com The ready-to-use tissues and assay platforms produced by InvivoSciences provide three-dimensional geometrics and physical environment for cells, bridging the gap between cell-based systems and isolated organ tissue systems or animal models, and can therefore act as model systems for chemical screening assays. This provides researchers with screening strategies that can assess the potential toxicity of new drugs–including those for cardiac applications–in accurate, predictive detection environments requiring less time and cost than corresponding studies using animals. Further, our ongoing commitment to research that pushes the boundaries of toxicity assessment in drug discovery helps reduce the risk of late-stage attrition in clinical trials. Company: ioos systems, LLC Booth: EC22 Media Contact: Scheer Phone: 858-453-7820 E-mail: info@ioossystems.com Web: www.ioossystems.com ioos provides biomaterials, micro particles and thin-film coatings for biomedical and tissue engineering applications. The company has designed various products for the application of drug-eluting polymeric matrices on combination devices, such as stents, which are currently used in critical production processes by major medical device and pharmaceutical companies. ioos has built an innovative technology platform that comprises, among others, Texsel nano-micro textured coating and Tutela biomimic membrane solutions. With ioos’ technology biostable and biodegradable materials and coatings can be fabricated and fine-tuned in terms of surface morphology for the particular application. Company: Knobbe Martens Booth: 4148 Media Contact: Sara McKibben Phone: 949-760-0404 E-mail: sara.mckibben@kmob.com Web: www.kmob.com Knobbe Martens serves clients around the globe, including public and private companies at various stages of growth from the startup to the Fortune 500. The firm counsels clients in all areas of intellectual property law and litigation. Founded in 1962, Knobbe Martens has one of the largest biotechnology practices in the west with more than 60 lawyers specializing in the industry. Company: Laureate Pharma, Inc. Booth: 2331 Media Contact: Mike Cavanaugh Phone: 609-919-3315 E-mail: mike.cavanaugh@laureatepharma.com Web: www.laureatepharma.com Laureate Pharma is a full-service contract biomanufacturing company offering services that accelerate new products from development through production. Our specialized services range from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. We focus on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Our expertise spans the area of clinical to modest commercial-scale production of monoclonal antibodies, interleukins, enzymes, antibody conjugates and radiolabeled antibodies. We have a fully integrated and FDA registered cGMP facility located in Princeton, New Jersey, staffed with experts and specialists in each critical area. Company: Life Science Analytics Booth: 231 Media Contact: Terence Hughes Phone: 570-687-9306 E-mail: thughes@medtrack.com Web: www.medtrack.com Life Science Analytics is the provider of MedTRACK, the industry leader of biomedical data. The web-based database, and its add-on components Venture and Japan, provide information on pipelines, financials, mechanisms and modes of action, trial and milestone data, management contact and networking tools, royalty information and patents. MedTRACK is the most comprehensive database of private and public biomedical companies with coverage on more than 12,000 biomedical companies worldwide. The information can be sorted by parameters such as disease, competitive products, or clinical trial stage making MedTRACK a well-furnished tool box with easy ways to find the data that you need! Company: Meissner Filtration Products, Inc. Booth: 5143 Media Contact: Karisa Koenig Phone: 805-388-9911 E-mail: karisa.koenig@meissner.com Web: www.meissner.com From clinical trials through full-scale production, Meissner offers leading filtration solutions for your manufacturing process. Meissner Technical Services (MTS) provides complete validation services, documentation and customer support to engineer filtration solutions that maximize efficiency, economics and safety. A global network of factory-trained distributors assists customers locally. Visit our booth to see TepoFlex(TM) biocontainers – NEW from the One- Touch(TM) family of single-use processing solutions. Exceptional in quality and function, TepoFlex(TM) is available in standard configurations from 5 – 1000 Liters. Custom configurations are also available. TepoFlex(TM) is fully documented and validated. For details on our complete line of microfiltration products and services, visit www.meissner.com. Company: MPI Research Booth: 1200 Media Contact: Peggy Foster Phone: 269-668-3336 ext.1617 E-mail: peggy.foster@mpiresearch.com Web: www.mpiresearch.com MPI Research is a full service Contract Research Organization that serves the biotech and pharmaceutical industries in meeting their preclinical and early clinical drug development research needs, from discovery to regulatory submission. Known for our state-of-the-art facilities, excellent study quality, regulatory experience, AAALAC accreditation, and GLP compliance, we partner with our Sponsors in delivering on time, high quality, innovative and cost-effective solutions. From single study protocols to multiple projects across our broad scope of services, we have the capacity and resources to bring your products to market as expeditiously as possible. For complete information, visit our website at www.mpiresearch.com. Company: Pennsylvania DCED Booth: 1201 PA Pavilion Media Contact: Ted Martin Phone: 717-214-5317 E-mail: themartin@state.pa.us Web: www.newPA.com Pennsylvania is the center of life science innovation –world-class basic research, emerging companies, mature industry, global pharmaceuticals and support organizations. Our $2 billion Life Sciences Enterprise commitment and $2.8 billion Economic Stimulus program are unrivaled. Make your business investment succeed. Put Pennsylvania in your future. Pennsylvania Department of Community and Economic Development Commonwealth Keystone Building 400 North Street, 4th Floor Harrisburg, PA 17120 (ph) 800-237-4363 www.newPA.com Company: Rose Business Solutions Booth: 5052 Media Contact: Heather Jarvis Phone: 858-794-9401 E-mail: heather.jarvis@rosebizinc.com Web: www.rosebizinc.com Rose Business Solutions is a Southern CA based Microsoft Gold Certified Partner. In business for over 17 years, we provide clients with the tools to streamline business processes and improve overall productivity. Specializing in Microsoft Dynamics Great Plains, Solomon, and CRM applications. Rose Business Solutions hosts, implements and trains on financials, procurement, manufacturing and distribution systems. Company: Savitz Law Offices, P.C. Booth: 1831 Media Contact: Bennett Savitz Phone: 617-723-7111 Email: BSavitz@ImmigrationOptions.com Web: www.ImmigrationOptions.com Savitz Law Offices, P.C. (www.ImmigrationOptions.com) provides legal services and expertise in all areas of immigration and nationality law both for corporate clients and individuals. In addition to obtaining temporary visas and permanent resident (Green Card) status for foreign nationals, we help clients to file to become naturalized U.S. Citizens, and to solve specific problems with the Immigration Service or other government agencies. Company: Speedel Ticker Symbol & Exchange: SWX: SPPN Media Contact: Richard Anderson, De Facto Phone: +44 (0) 207 861 3838 E-mail: richard.anderson@defacto.com Web: www.speedel.com Speedel is a public biopharmaceutical company that seeks to create value for patients and partners by developing innovative therapies for cardiovascular and metabolic diseases and is a world leader in renin inhibition. Our lead compound SPP100 (Tekturna/Rasilez1), the first-in-class direct renin inhibitor, was in-licensed from Novartis in 1999 and licensed-back in 2002 for further development and commercialisation; SPP100 was approved in March (USA) and August (EU) 2007. Speedel’s pipeline covers four different modes of action; besides SPP100 it includes three candidates in Phase II, two candidates in Phase I, plus several pre-clinical projects. (1) Tekturna/Rasilez(R) are Novartis trademarks Company: Stanbio Life Sciences Booth: 5147 Media Contact: Tony Hubbard Phone: 574-264-7384 E-mail: thubbard@stanbio.com Web: www.stanbiols.com Since 1983, Stanbio Life Sciences has provided bacterial fermentation services for various life science applications. We now offer our production and downstream processing capabilities to life science companies requiring enzymes and proteins for their custom applications. Our contract facility is designed to produce enzymes and proteins that meet our customers’ specifications using various native and recombinant microorganisms, including organisms grown at high density. We continually work with customers to maximize product yields from their microbial systems. Our enzymes and proteins are designed to provide better specificity, selectivity and to increase the stability of test systems and other clinically important applications. Company: SynCo Bio Partners Media Contact: Kevin Payne, De Facto Communications Phone: +44 (0) 207 861 3838 E-mail: k.payne@defacto.com Web: www.syncobio.com SynCo Bio Partners is a GMP contract manufacturing organisation which offers a fully integrated range of services in biopharmaceutical manufacturing and supports companies from the earliest stage in process development, through clinical trials to market supply. With a track record of expertise in the production of recombinant proteins and vaccines, SynCo collaborates with a number of leading Biotech and Pharmaceutical companies world wide. Company: Xceleron Booth: 3643 Media Contact: Liz Wyatt, De Facto Communications Phone: +44 (0) 207 861 3838 E-mail: l.wyatt@defacto.com Web: www.xceleron.com Xceleron is the global leader in predictive clinical research to enable smarter, safer drug development decisions. Leveraging its proprietary methods and ultra-sensitive technology platform, Xceleron delivers the earliest possible, most relevant human insights to its clients enabling smarter and safer drug development decision-making in terms of productivity, pipeline value and profit. Xceleron maintains ongoing client engagements with 15 of the 20 largest pharmaceutical companies in the world and has analyzed more than 200 molecules to date.
Note to Editors: Business Wire’s PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire’s online event calendar. For information, email tradeshow (at) businesswire.com.